CD4 and myeloid sarcoma: A case-control study was performed by Ghadiri et al., and forty RRSM patients were enrolled (including 20 relapsing and 20 remitting MS patients); they detected the expression levels of several miRNAs in CD4 + T cells using RT-PCR and further evaluated the diagnostic value of these miRNAs for MS.